You are here:
Archived: aliskiren (Rasilez)
Advice
In the absence of a submission from the holder of the marketing authorisation
aliskiren (Rasilez) is not recommended for use within NHSScotland for the treatment of essential hypertension.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Drug Details
| Drug Name: | aliskiren (Rasilez) |
|---|---|
| SMC Drug ID: | 462/08 |
| Manufacturer: | Novartis Pharmaceuticals UK Ltd |
| Indication: | for the treatment of essential hypertension |
| BNF Category: | |
| Sub Category: | 2.6 Nitrates*** calcium-channel blockers*** and other antianginal drugs |
| Submission Type: | Non submission |
| Status: | Not Recommended |
| Date Advice Published: | 12 May 2008 |
Current Advice
| aliskiren (Rasilez)_resub | Resubmission | 8 February 2010 |
Archived Advice
| aliskiren (Rasilez)_fullsub | Full submission | 12 January 2009 |